Selected research
Industry Research
Circulating Tumor Cell(CTC)Detection Industry Research Report 2026
Market perspective
The global Circulating Tumor Cell(CTC)Detection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Circulating Tumor Cell(CTC)Detection market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Circulating Tumor Cell(CTC)Detection market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Circulating Tumor Cell(CTC)Detection market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Circulating Tumor Cell(CTC)Detection include Rarecyte, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE and Qiagen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Circulating Tumor Cell(CTC)Detection market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Circulating Tumor Cell(CTC)Detection.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Circulating Tumor Cell(CTC)Detection Market by Company
Rarecyte
ANGLE plc
Biocept Inc.
Bio-Rad Laboratories Inc.
Fluxion Biosciences Inc.
F. Hoffmann-La Roche AG
Sysmex Europe SE
Qiagen
Circulating Tumor Cell(CTC)Detection Segment by Type
Epithelial Cell Phenotype
Mesenchymal Cell Phenotype
Mixed Epithelial-Mesenchymal Phenotype
Circulating Tumor Cell(CTC)Detection Segment by Application
Cancer Diagnosis
Tumor Dynamic Assessment
Tumor Recurrence Monitoring
Circulating Tumor Cell(CTC)Detection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cell(CTC)Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cell(CTC)Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cell(CTC)Detection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Circulating Tumor Cell(CTC)Detection companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Epithelial Cell Phenotype
- Mesenchymal Cell Phenotype
- Mixed Epithelial-Mesenchymal Phenotype
Applications
- Cancer Diagnosis
- Tumor Dynamic Assessment
- Tumor Recurrence Monitoring
Companies covered
- Rarecyte
- ANGLE plc
- Biocept Inc.
- Bio-Rad Laboratories Inc.
- Fluxion Biosciences Inc.
- F. Hoffmann-La Roche AG
- Sysmex Europe SE
- Qiagen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Circulating Tumor Cell(CTC)Detection by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Epithelial Cell Phenotype
- 2.2.3 Mesenchymal Cell Phenotype
- 2.2.4 Mixed Epithelial-Mesenchymal Phenotype
- 2.3 Circulating Tumor Cell(CTC)Detection by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer Diagnosis
- 2.3.3 Tumor Dynamic Assessment
- 2.3.4 Tumor Recurrence Monitoring
- 2.4 Assumptions and Limitations
3 Circulating Tumor Cell(CTC)Detection Breakdown Data by Type
- 3.1 Global Circulating Tumor Cell(CTC)Detection Historic Market Size by Type (2021-2026)
- 3.2 Global Circulating Tumor Cell(CTC)Detection Forecasted Market Size by Type (2027-2032)
4 Circulating Tumor Cell(CTC)Detection Breakdown Data by Application
- 4.1 Global Circulating Tumor Cell(CTC)Detection Historic Market Size by Application (2021-2026)
- 4.2 Global Circulating Tumor Cell(CTC)Detection Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Circulating Tumor Cell(CTC)Detection Market Perspective (2021-2032)
- 5.2 Global Circulating Tumor Cell(CTC)Detection Growth Trends by Region
- 5.2.1 Global Circulating Tumor Cell(CTC)Detection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Circulating Tumor Cell(CTC)Detection Historic Market Size by Region (2021-2026)
- 5.2.3 Circulating Tumor Cell(CTC)Detection Forecasted Market Size by Region (2027-2032)
- 5.3 Circulating Tumor Cell(CTC)Detection Market Dynamics
- 5.3.1 Circulating Tumor Cell(CTC)Detection Industry Trends
- 5.3.2 Circulating Tumor Cell(CTC)Detection Market Drivers
- 5.3.3 Circulating Tumor Cell(CTC)Detection Market Challenges
- 5.3.4 Circulating Tumor Cell(CTC)Detection Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Circulating Tumor Cell(CTC)Detection Players by Revenue
- 6.1.1 Global Top Circulating Tumor Cell(CTC)Detection Players by Revenue (2021-2026)
- 6.1.2 Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Players (2021-2026)
- 6.2 Global Circulating Tumor Cell(CTC)Detection Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Circulating Tumor Cell(CTC)Detection Head Office and Area Served
- 6.4 Global Circulating Tumor Cell(CTC)Detection Players, Product Type & Application
- 6.5 Global Circulating Tumor Cell(CTC)Detection Manufacturers Established Date
- 6.6 Global Circulating Tumor Cell(CTC)Detection Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
- 7.2 North America Circulating Tumor Cell(CTC)Detection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 7.4 North America Circulating Tumor Cell(CTC)Detection Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
- 8.2 Europe Circulating Tumor Cell(CTC)Detection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 8.4 Europe Circulating Tumor Cell(CTC)Detection Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
- 9.2 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
- 10.2 South America Circulating Tumor Cell(CTC)Detection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 10.4 South America Circulating Tumor Cell(CTC)Detection Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
- 11.2 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Rarecyte
- 12.1.1 Rarecyte Company Information
- 12.1.2 Rarecyte Business Overview
- 12.1.3 Rarecyte Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.1.4 Rarecyte Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.1.5 Rarecyte Recent Developments
- 12.2 ANGLE plc
- 12.2.1 ANGLE plc Company Information
- 12.2.2 ANGLE plc Business Overview
- 12.2.3 ANGLE plc Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.2.4 ANGLE plc Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.2.5 ANGLE plc Recent Developments
- 12.3 Biocept Inc.
- 12.3.1 Biocept Inc. Company Information
- 12.3.2 Biocept Inc. Business Overview
- 12.3.3 Biocept Inc. Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.3.4 Biocept Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.3.5 Biocept Inc. Recent Developments
- 12.4 Bio-Rad Laboratories Inc.
- 12.4.1 Bio-Rad Laboratories Inc. Company Information
- 12.4.2 Bio-Rad Laboratories Inc. Business Overview
- 12.4.3 Bio-Rad Laboratories Inc. Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.4.4 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.4.5 Bio-Rad Laboratories Inc. Recent Developments
- 12.5 Fluxion Biosciences Inc.
- 12.5.1 Fluxion Biosciences Inc. Company Information
- 12.5.2 Fluxion Biosciences Inc. Business Overview
- 12.5.3 Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.5.4 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.5.5 Fluxion Biosciences Inc. Recent Developments
- 12.6 F. Hoffmann-La Roche AG
- 12.6.1 F. Hoffmann-La Roche AG Company Information
- 12.6.2 F. Hoffmann-La Roche AG Business Overview
- 12.6.3 F. Hoffmann-La Roche AG Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.6.4 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.6.5 F. Hoffmann-La Roche AG Recent Developments
- 12.7 Sysmex Europe SE
- 12.7.1 Sysmex Europe SE Company Information
- 12.7.2 Sysmex Europe SE Business Overview
- 12.7.3 Sysmex Europe SE Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.7.4 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.7.5 Sysmex Europe SE Recent Developments
- 12.8 Qiagen
- 12.8.1 Qiagen Company Information
- 12.8.2 Qiagen Business Overview
- 12.8.3 Qiagen Revenue in Circulating Tumor Cell(CTC)Detection Business (2021-2026)
- 12.8.4 Qiagen Circulating Tumor Cell(CTC)Detection Product Portfolio
- 12.8.5 Qiagen Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst